Please ENTER to search
Please ENTER to search
138926-19-9
Bisphosphonate (bone resorption inhibitor)
BONIVA
Treatment of Osteoporosis
Bisphosphonates are taken into the bone where they bind to hydroxyapatite. Bone resorption by osteoclasts causes local acidification, releasing the bisphosphonate, which is taken into the osteoclast by fluid-phase endocytosis. Endocytic vesicles become acidified, releasing bisphosphonates into the cytosol of osteoclasts where they act.
Osteoclasts mediate resorption of bone. When osteoclasts bind to bone they form podosomes, ring structures of F-actin.6 Disruption of the podosomes causes osteoclasts to detach from bones, preventing bone resorption. Nitrogen containing bisphosphonates such as ibandronate are known to induce apoptosis of hematopoietic tumor cells by inhibiting the components of the mevalonate pathway farnesyl diphosphate synthase, farnesyl diphosphate, and geranylgeranyl diphosphate.
These components are essential for post-translational prenylation of GTP-binding proteins like Rap1. The lack of prenylation of these proteins interferes with their function, and in the case of Rap1, leads to apoptosis. ibandronate also activated caspase-3 which contribute to apoptosis.
For the treatment and prevention of osteoporosis in postmenopausal women.
Disclaimer: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement. The liability of any sale into such protected markets is at buyer's risk.
Request you to provide all details mentioned in the form along with your business requirement. It will help us route your query to the appropriate person.
